Al Jinan الجنان


This study aims at the investigation of the effect of prolactinemia on male fertility. The study group included 30 males with infertility problems and accompanied with high prolactin hormone levels in the blood. Hormone and seminal fluid analyses were performed before and after treatments with Cabergoline (DostinexTM), and results were comparable to those observed in a control group consisting of 14 healthy males. Results have shown that the increase in prolactin levels led to flaws in sexual hormone concentrations and to a decrease in sperm count and mobility compared to the control group. For this purpose, two groups were tested. The first group consisted of males with sperm counts ranging from 0 to one million. The second group consisted of males with sperm counts between 1 million and 14 millions. Results were indicative to a decrease in Prolactin levels from 24 ng/ml to 14 ng/ml in the first group and to a decrease from 27 ng/ml to 12 ng/ml in the second group. Sperm count increased from 60,000 to 12,000,000 in the first group compared to an increase from 7,000,000 to 17,000,000 in the second group. In addition, there was a sperm mobility improvement noticed in both groups (increased from 8% to 34% in the first group and from 32% to 41% in the second group). In brief, the present results indicate that Cabergoline leads to a decrease in prolactin levels in the blood, which, subsequently, improves sperm count and mobility in males. The values obtained in the present study reached levels that made fertility possible in treated males